Physician profile
Chelsea Flowe
NPI 1871682815
$8,994.53
in general payments reported to CMS, 2019-2025
34 companies · $2,253 in 2025
The $2,253 reported for 2025 was more than what 95% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $771 · 2022: $2,066 · 2023: $2,055 · 2024: $1,849 · 2025: $2,253.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,157.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,100.03 | 2022-2025 | Jardiance, Mounjaro, Zepbound |
| Amgen INC. | $964.53 | 2021-2025 | Evenity, Prolia, Prolia |
| Novo Nordisk INC | $961.05 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $706.67 | 2021-2025 | Jardiance, Synjardy, Tradjenta |
| Abbvie INC. | $587.68 | 2021-2025 | |
| Dexcom, INC. | $585.22 | 2021-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Tandem Diabetes Care, INC. | $496.48 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Abbott Laboratories | $454.44 | 2021-2025 | Freestyle Libre 3 |
| Radius Health, INC. | $377.16 | 2022-2025 | Tymlos |
| Medtronic, INC. | $376.04 | 2021-2025 | Minimed 770g, Minimed 780g |
| Astrazeneca Pharmaceuticals LP | $357.03 | 2021-2024 | Farxiga |
| Insulet Corporation | $338.20 | 2021-2025 | Omnipod, Omnipod |
| Mannkind Corporation | $335.39 | 2022-2024 | Afrezza |
| Sanofi-Aventis U.S. LLC | $259.65 | 2021-2023 | |
| Xeris Pharmaceuticals, INC. | $164.58 | 2021-2025 | Gvoke Hypopen |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $125.00 | 2025 | Voquezna |
| Kyowa Kirin, INC. | $115.48 | 2023-2025 | Crysvita |
| Bayer Healthcare Pharmaceuticals INC. | $111.09 | 2021-2022 | |
| Ultragenyx Pharmaceutical INC. | $104.02 | 2022-2024 | Crysvita |
| Recordati_rare_diseases_inc. | $54.21 | 2023-2024 | Isturisa, Signifor Lar |
| Antares Pharma, INC. | $51.95 | 2023-2025 | Xyosted, Nocdurna, Tlando |
| Pfizer INC. | $47.28 | 2022-2023 | |
| Halozyme INC | $44.19 | 2023 | |
| Ascendis Pharma Endocrinology INC | $33.87 | 2024-2025 | Yorvipath |
| Verity Pharmaceuticals INC. | $33.87 | 2025 | Tlando |
| Madrigal Pharmaceuticals | $31.14 | 2025 | Rezdiffra |
| Glaxosmithkline, LLC. | $30.11 | 2025 | Shingrix |
| Sandoz INC. | $28.23 | 2025 | Jubbonti |
| Kowa Pharmaceuticals America, INC. | $24.51 | 2022 | |
| Tolmar, INC. | $23.89 | 2025 | Jatenzo |
| Becton, Dickinson and Company | $22.61 | 2022 | |
| Cequr Corporation | $20.33 | 2023 | Cequr Simplicity |
| Horizon Therapeutics Plc | $14.45 | 2023 | Tepezza |
| Amryt Pharma Holdings LTD | $14.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chelsea Flowe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.